Robert Hazlett
Stock Analyst at BTIG
(1.30)
# 3,654
Out of 5,090 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.43 | +273.25% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $56.90 | +5.45% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.59 | +780.50% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $4.27 | +23,319.20% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $149.22 | -34.33% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $10.36 | +479.15% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $5.82 | +982.47% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $11.07 | +161.97% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.20 | +2,166,566.67% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.54 | +289.61% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $16.43 | +9.56% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.43
Upside: +273.25%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $56.90
Upside: +5.45%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.59
Upside: +780.50%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $4.27
Upside: +23,319.20%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $149.22
Upside: -34.33%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $10.36
Upside: +479.15%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $5.82
Upside: +982.47%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $11.07
Upside: +161.97%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.20
Upside: +2,166,566.67%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.54
Upside: +289.61%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $16.43
Upside: +9.56%